T1	Intervention 10 34	rosuvastatin monotherapy
T2	Intervention 58 88	fenofibrate or ω-3 fatty acids
T3	Intervention 92 103	lipoprotein
T4	Intervention 147 183	dyslipidaemia and metabolic syndrome
T5	Intervention 204 222	triglycerides (TG)
T6	Intervention 234 278	high-density lipoprotein cholesterol (HDL-C)
T7	Intervention 308 352	small dense low density lipoproteins (sdLDL)
T8	Intervention 380 398	metabolic syndrome
T9	Intervention 452 476	rosuvastatin monotherapy
T10	Intervention 512 573	fenofibrate or ω-3 fatty acids on the lipoprotein subfraction
T11	Intervention 605 618	dyslipidaemia
T12	Intervention 676 744	low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200 mg/dl
T13	Intervention 748 800	rosuvastatin monotherapy 40 mg/day (R group, n = 30)
T14	Intervention 804 826	rosuvastatin 10 mg/day
T15	Intervention 841 928	fenofibrate 200 mg/day (RF group, n = 30) or ω-3 fatty acids 2 g/day (Rω group, n = 30)
T16	Intervention 990 1045	(24, 23 and 24 in the R, RF and Rω groups respectively)
T17	Intervention 1096 1119	lipoprotein subfraction
T18	Intervention 1146 1183	polyacrylamide 3% gel electrophoresis
T19	Intervention 1202 1205	LDL
T20	Intervention 1290 1292	RF
T21	Intervention 1449 1451	RF
T22	Intervention 1473 1475	RF
T23	Intervention 1497 1529	HDL-C levels (by 7.7%, p < 0.05)
T24	Intervention 1569 1572	HDL
T25	Intervention 1610 1613	HDL
T26	Intervention 1588 1599	cholesterol
T27	Intervention 1656 1664	R and Rω
T28	Intervention 1682 1690	regimens
T29	Intervention 1706 1709	LDL
T30	Intervention 1716 1718	RF
T31	Intervention 1796 1799	HDL
